Background: Transcatheter renal denervation (TRD) obviously may be done with endocardial ablation systems which allow exactly the same mode/parameters of energy delivery while small 5-7F endocardial catheters may be easily manipulated in renal artery. However, in contrast with novel renal ablation devices still at the development stage, endocardial ablation systems are mature equipment with proven success, predictable behavior and lower price. Greater length/diameter of endocardial ablation electrode provide greater contact area meaning proportionally lower current density and thereby risk of overheating, i.e. more safe ablation. Objective: To assess the safety and efficacy of TRD done by endocardial ablation system. Methods: We performed bilateral TRD using endocardial ablation catheter 5F, 4 mm in 52 patients (aged 53.7±9.6 years, 27 male) with true drug-resistant hypertension. Sequentially 4-8 point RF ablations separated radially and axially in renal artery and segmental branches were done in temperature-control mode with target T=60 C. All patients were instructed to continue existed pharmacotherapy. Efficacy was evaluated by the changes in office and ambulatory BP at 6 and 12 months after TRD. Safety endpoints included adverse events, changes in renal blood flow (ultrasound doppler flowmetry) and renal function (proteinuria, serum creatinine) at 1 week, 6 and 12 months after TRD (NCT01499810 at ClinicalTrials.gov). Results: No acute damage of renal arteries from RF ablation was detected by intraoperational angiography. There were 7 minor periprocedural events typical for endovascular procedures and non-related to RF ablation. At the time of this analysis 39 and 25 patients completed respectively 6 and 12 months follow-up. No significant changes in renal blood flow or renal function were detected at 6 or 12 months after TRD. Office BP dropped significantly by -27,5 (p<0,001)/-13,9 p<0,001 (mmHg, systolic/diastolic) at 6 months and then further decreased by -32,6 (p<0,001)/-15,5 p<0,001 at 12 months after TRD. The lowering of mean 24-h BP was quite modest at 6 months -11,5 (p<0,001)/-6,8 (p<0,001) however also continued to decrease and reached powerful level of -15,4 (p<0,001)/-10,4 (p<0,001) at 12 months follow-up. Conclusions: TRD done by endocardial ablation system is safe in patients with resistant hypertension and causes significant long-term lowering of BP which tends to increase over time.